Olive Health Care Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Olive Health Care Pharmaceutical Export Portfolio Dataset — 4 Products, $5.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Olive Health Care — Pharmaceutical Exporter Profile (2026) | 4 Products, $5.2M Trade | TransData Nexus

Olive Health Care

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $5.2M Total Trade · DGFT Verified

Olive Health Care is an Indian pharmaceutical exporter with a total trade value of $5.2M across 4 products in 4 therapeutic categories. Based on 108 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Paracetamol ($4.5M), Omega ($429.9K), Cyclosporine ($198.6K).

Olive Health Care — Export Portfolio & Destination Treemap

Olive Health Care pharmaceutical export portfolio — 4 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Olive Health Care? — Company Overview & Market Position

Olive Health Care is a fully integrated Indian pharmaceutical company specializing in the development, manufacturing, and marketing of a broad range of soft gelatin formulations. Established over four decades ago, the company has built a strong regulatory and infrastructural foundation to support its research and development (R&D) and growth strategies in global markets. Operating from its headquarters in Mumbai, Maharashtra, Olive Health Care has expanded its presence with three state-of-the-art manufacturing facilities across India. These facilities hold approvals from the World Health Organization's Good Manufacturing Practices (WHO GMP), the U.S. Food and Drug Administration (FDA), and ISO certifications for quality, environment, and occupational health and safety.

The company's product portfolio is diverse, encompassing nutraceuticals, over-the-counter (OTC) products, prescription medications, and innovative technologies. Olive Health Care has adopted a flexible business model, offering services ranging from contract and toll manufacturing to comprehensive development and manufacturing projects. This adaptability, combined with its strong R&D capabilities, positions Olive Health Care as a competitive player in the global pharmaceutical market.

What Does Olive Health Care Export? — Product Portfolio Analysis

Top Products by Export Value

1Paracetamol

Product Portfolio — Top 4 by Export Value

Olive Health Care exports 4 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Paracetamol	Analgesics & Antipyretics	$4.5M	89	1.2%	11
2	Omega	Nutritional Supplements	$429.9K	9	2.3%	4
3	Cyclosporine	Immunosuppressants	$198.6K	7	1.6%	9
4	Extract	Ayurvedic & Herbal Products	$150.0K	3	1.2%	10

Olive Health Care exports 4 pharmaceutical products across 4 therapeutic categories with a total export value of $5.2M. The top category is Analgesics & Antipyretics (85.1% of portfolio), followed by Nutritional Supplements (8.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Olive Health Care — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Olive Health Care operates three advanced manufacturing facilities in India, each designed to meet stringent international standards. These facilities are strategically located to cater to both domestic and international markets, ensuring efficient production and distribution. The manufacturing plants are equipped with cutting-edge technology and adhere to Good Manufacturing Practices (GMP), as evidenced by their approvals from the WHO and the U.S. FDA.

3Key Leadership

The leadership team at Olive Health Care comprises experienced professionals dedicated to steering the company towards its strategic objectives. While specific names and roles are not publicly disclosed, the company's management is known for its commitment to quality and innovation. The leadership's focus on R&D and regulatory compliance has been instrumental in establishing Olive Health Care's reputation in the global pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Olive Health Care Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Olive Health Care has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold approvals from the U.S. FDA and the EU health and sanitary authorities, facilitating access to these markets. Additionally, Olive Health Care has obtained GMP certification from the Therapeutic Goods Administration (TGA) in Australia, further expanding its global footprint.

2Emerging Markets

In addition to its presence in regulated markets, Olive Health Care has made strategic inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, as demonstrated by its WHO GMP approvals, has enabled it to navigate the regulatory landscapes of these regions effectively. This global approach underscores Olive Health Care's commitment to expanding its reach and impact in diverse healthcare settings.

3Geographic Strategy

Olive Health Care's geographic strategy reflects a balanced approach to market diversification and risk management. By establishing a presence in both regulated and emerging markets, the company mitigates concentration risks and leverages growth opportunities across different regions. This strategic direction aligns with Olive Health Care's goal of becoming a global leader in soft gelatin formulations, ensuring sustainable growth and resilience in the competitive pharmaceutical landscape.

Olive Health Care — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Olive Health Care's manufacturing facilities are registered with the U.S. FDA, indicating compliance with U.S. regulatory standards. The company has undergone FDA inspections, which assess adherence to Good Manufacturing Practices (GMP). While specific details of these inspections are not publicly disclosed, the FDA's oversight underscores Olive Health Care's commitment to maintaining high-quality manufacturing processes.

2WHO & EU GMP

The company's manufacturing facilities hold approvals from the World Health Organization's Good Manufacturing Practices (WHO GMP), ensuring adherence to international quality standards. Additionally, Olive Health Care has obtained certification from the EU health and sanitary authorities, facilitating exports to EU and allied nations. These certifications reflect Olive Health Care's dedication to maintaining high-quality manufacturing processes and meeting global regulatory requirements.

3CDSCO & Indian Regulatory

In India, Olive Health Care operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO). The company's manufacturing facilities hold the necessary licenses and approvals from CDSCO, ensuring compliance with national pharmaceutical regulations. This adherence to CDSCO standards underscores Olive Health Care's commitment to maintaining high-quality manufacturing processes and meeting domestic regulatory requirements.

Olive Health Care — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the soft gelatin formulation segment, Olive Health Care faces competition from both domestic and international pharmaceutical companies. While specific market share data is not publicly disclosed, Olive Health Care's adherence to international quality standards and its flexible business model position it favorably in the market. The company's focus on R&D and regulatory compliance further enhances its competitive edge, enabling it to meet diverse customer needs and maintain a strong market presence.

2Key Differentiators

Olive Health Care's key differentiators include its exclusive focus on soft gelatin formulations, a flexible business model that accommodates both contract manufacturing and comprehensive development projects, and a robust R&D infrastructure. These strengths enable the company to offer customized solutions, maintain high-quality standards, and adapt to evolving market demands effectively.

3Strategic Position

Olive Health Care's current strategic direction emphasizes the development and manufacturing of soft gelatin formulations, with a strong focus on R&D and regulatory compliance. The company's future outlook includes expanding its global presence, particularly in emerging markets, and enhancing its product portfolio to include innovative delivery technologies. This strategic approach aims to position Olive Health Care as a leading provider of soft gelatin formulations worldwide.

Buyer Due Diligence Brief — Evaluating Olive Health Care as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Olive Health Care has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's adherence to international quality standards, as evidenced by its WHO GMP and FDA approvals, reflects its commitment to reliability and product excellence. The absence of recent regulatory actions further indicates the company's consistent compliance with industry standards. However, stakeholders are encouraged to conduct thorough due diligence and consult official regulatory databases for the most current information.

2Certifications to Verify

Importers should verify the following certifications when considering Olive Health Care as a supplier:

FDA Registration: Confirm the company's manufacturing facilities are registered with the U.S. FDA.

WHO GMP Certification: Ensure the manufacturing facilities hold WHO GMP approvals.

EU GMP Certification: Verify certification from the EU health and sanitary authorities.

Frequently Asked Questions — Olive Health Care

How many pharmaceutical products does Olive Health Care export from India?

Olive Health Care exports 4 pharmaceutical products across 4 therapeutic categories. The top exports are Paracetamol ($4.5M), Omega ($429.9K), Cyclosporine ($198.6K), Extract ($150.0K). Total export value is $5.2M.

What is Olive Health Care's total pharmaceutical export value?

Olive Health Care's total pharmaceutical export value is $5.2M, based on 108 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Olive Health Care cover?

Olive Health Care exports across 4 therapeutic categories. The largest are Analgesics & Antipyretics (85.1%, 1 products), Nutritional Supplements (8.2%, 1 products), Immunosuppressants (3.8%, 1 products).

Get Full Olive Health Care Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.